Advanced Search

Journal of Traditional Chinese Medicine >

2023 , Vol. 43 >Issue 1: 51 - 59

DOI: https://doi.org/10.19852/j.cnki.jtcm.2023.01.006

Original articles

Comparing the effects of three decoctions for coronavirus disease 2019 on severe acute respiratory syndrome coronavirus 2-related toll-like receptors-mediated inflammations

  • Ximeng LI ,
  • Yuan KANG ,
  • Wenjing LI ,
  • Zhuangzhuang LIU ,
  • Zhenlu XU ,
  • Xiaoyu ZHANG ,
  • Runlan CAI ,
  • Yuan GAO ,
  • Yun QI
Expand
  • Department of Pharmacology and Toxicology, Institute of Medicinal Plant Development, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100193, China
GAO Yuan, Department of Pharmacology and Toxicology, Institute of Medicinal Plant Development, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100193, China. ygao@implad.ac.cn.Telephone: +86-10-57833225
QI Yun, Department of Pharmacology and Toxicology, Institute of Medicinal Plant Development, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100193, China. yqi@implad.ac.cn

Received date: 2022-06-12

  Accepted date: 2022-09-24

  Online published: 2023-01-10

Supported by

Effect and Mechanisms Research of Hua-shi-Bai-Du Formula on the Cytokine Storm in COVID-19 Based on Innate and Acquired Immunity(82074091);Effects and Mechanisms research of Qing-Fei-Pai-Du-Tang on the Cytokine Storm in COVID-19 Based on TLRs Signaling(M21014);CAMS Innovation Fund for Medical Sciences (CIFMS)(2021-I2M-1-028);New Technology Research on Discovery and Evaluation of Unknown Small Molecular Effective Substances in Natural Products and 2021-I2M-1-031 (Key Technology Research on Quality Evaluation and Resource Guarantee of Rare Medicinal Plants

Fold

Cite this article

Ximeng LI , Yuan KANG , Wenjing LI , Zhuangzhuang LIU , Zhenlu XU , Xiaoyu ZHANG , Runlan CAI , Yuan GAO , Yun QI . Comparing the effects of three decoctions for coronavirus disease 2019 on severe acute respiratory syndrome coronavirus 2-related toll-like receptors-mediated inflammations[J]. Journal of Traditional Chinese Medicine, 2023 , 43(1) : 51 -59 . DOI: 10.19852/j.cnki.jtcm.2023.01.006

References

1 Hoffmann M, Kleine-Weber H, Schroeder S, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease pnhibitor. Cell 2020;181: 271-80. e8.
2 Junqueira C, Crespo ?, Ranjbar S, et al. FcγR-mediated SARS-CoV-2 infection of monocytes activates inflammation. Nature 2022; 606: 576-84.
3 Sefik E, Qu R, Junqueira C, et al. Inflammasome activation in infected macrophages drives COVID-19 pathology. Nature 2022; 606: 585-93.
4 Lowery SA, Sariol A, Perlman S. Innate immune and inflammatory responses to SARS-CoV-2: implications for COVID-19. Cell Host Microbe 2021; 29: 1052-62.
5 Xu G, Qi F, Li HJ, et al. The differential immune responses to COVID-19 in peripheral and lung revealed by single-cell RNA sequencing. Cell Discov 2020; 6: 73.
6 Xiong Y, Liu Y, Cao L, et al. Transcriptomic characteristics of bronchoalveolar lavage fluid and peripheral blood mononuclear cells in COVID-19 patients. Emerg Microbes Infect 2020; 9: 761-70.
7 Salvi V, Nguyen HO, Sozio F, et al. SARS-CoV-2-associated ssRNAs activate inflammation and immunity via TLR7/8. JCI Insight 2021; 6: e150542.
8 Bortolotti D, Gentili V, Rizzo S, et al. TLR3 and TLR7 RNA sensor activation during SARS-CoV-2 Infection. Microorganisms 2021; 9: 1820.
9 Zhao Y, Kuang M, Li J, et al. SARS-CoV-2 spike protein interacts with and activates TLR41. Cell Res 2021;
9 31:818-20, 825.
10 Shirato K, Kizaki T. SARS-CoV-2 spike protein S1 subunit induces pro-inflammatory responses via toll-like receptor 4 signaling in murine and human macrophages. Heliyon 2021; 7: e06187.
11 Yazdanpanah F, Hamblin MR, Rezaei N. The immune system and COVID-19: friend or foe? Life Sci 2020; 256: 117900.
12 Sallenave JM, Guillot L. Innate immune signaling and proteolytic pathways in the resolution or exacerbation of SARS-CoV-2 in Covid-19: key therapeutic targets? Front Immunol 2020; 11: 1229.
13 Pantazi I, Al-Qahtani AA, Alhamlan FS, et al. SARS-CoV-2/ACE 2 interaction suppresses IRAK-M expression and promotes pro-inflammatory cytokine production in macrophages. Front Immunol 2021; 12: 683800.
14 Liang N, Ma Y, Wang J, et al. Traditional Chinese Medicine guidelines for coronavirus disease 2019. J Tradit Chin Med 2020; 40: 891-6.
15 Shi N, Liu B, Liang N, et al. Association between early treatment with Qingfei Paidu decoction and favorable clinical outcomes in patients with COVID-19: a retrospective multicenter cohort study. Pharmacol Res 2020; 161: 105290.
16 Wang Q, Zhu H, Li M, et al. Efficacy and safety of Qingfei Paidu decoction for yreating COVID-19: a systematic review and Meta-analysis. Front Pharmacol 2021; 12: 688857.
17 Xiong WZ, Wang G, Du J, Ai W. Efficacy of herbal medicine (Xuanfei Baidu decoction) combined with conventional drug in treating COVID-19: a pilot randomized clinical trial. Integr Med Res 2020; 9: 100489.
18 Pan X, Dong L, Yang L, Chen D, Peng C. Potential drugs for the treatment of the novel coronavirus pneumonia (COVID-19) in China. Virus Res 2020; 286: 198057.
19 Wang Y, Sang X, Shao R, et al. Xuanfei Baidu decoction protects against macrophages induced inflammation and pulmonary fibrosis via inhibiting IL-6/STAT3 signaling pathway. J Ethnopharmacol 2022; 283: 114701.
20 Li Y, Li B, Wang P, Wang Q. Traditional Chinese Medicine, Qingfei Paidu decoction and Xuanfei Baidu decoction, inhibited cytokine production via NF-κB signaling pathway in macrophages: implications for Coronavirus Disease 2019 (COVID-19) Therapy. Front Pharmacol 2021; 12: 722126.
21 Wei WL, Wu SF, Li HJ, et al. Chemical profiling of Huashi Baidu prescription, an effective anti-COVID-19 TCM formula, by UPLC-Q-TOF/MS. Chin J Nat Med 2021; 19: 473-80.
22 Xu X, Xia J, Zhao S, et al. Qing-Fei-Pai-Du decoction and wogonoside exert anti-inflammatory action through down-regulating USP14 to promote the degradation of activating transcription factor 2. FASEB J 2021; 35: e21870.
23 Wang Y, Wang X, Li Y, et al. Xuanfei Baidu decoction reduces acute lung injury by regulating infiltration of neutrophils and macrophages via PD-1/IL17A pathway. Pharmacol Res 2022; 176: 106083.
24 National Administration of Traditional Chinese Medicine. Management specification for the decoction room of Traditional Chinese Medicine in medical institutions. Yi Zheng Si online, 2009-03-27, cited cn/yizhengsi/gongzuodongtai/2018-03-25/6577.html.
25 Shen A, Zhou W, Xiong L, et al. Chemical profiling of Qingfei Paidu decoction by triplex off-line two-dimensional liquid chromatography coupled with quadrupole time-of-flight mass spectrometry. J Sep Sci 2022; 45: 1162-9.
26 Wang X, Quan S, Zhang H, Song X, Zhang J, Liu D. Development and validation of a sensitive UPLC-Q-TOF-MS/MS for the measurement of nine components in rat plasma and tissues and its application to pharmacokinetics and tissue distribution studies with Xuanfei Baidu granules. Curr Drug Metab 2022; 23: 150-63.
27 Zhang X, Kang Y, Li X, et al. Potentilla discolor ameliorates LPS-induced inflammatory responses through suppressing NF-κB and AP-1 pathways. Biomed Pharmacother 2021; 144: 112345.
28 Yanagisawa S, Koarai A, Sugiura H, et al. Oxidative stress augments toll-like receptor 8 mediated neutrophilic responses in healthy subjects. Respir Res 2009; 10: 50.
29 Tosar JP, Segovia M, Castellano M, et al. Fragmentation of extracellular ribosomes and tRNAs shapes the extracellular RNAome. Nucleic Acids Res 2020; 48: 12874-88.
30 Diebner HH, Reinke S, R?sen-Wolff A, Winkler S. A linetic response model for standardized regression analyses of inflammation-triggered hypothermic body temperature-time courses in Mice. Front Physiol 2021; 12: 634510.
31 Moriez R, Salvador-Cartier C, Theodorou V, Fioramonti J, Eu-tamene H, Bueno L. Myosin light chain kinase is involved in lipo-polysaccharide-induced disruption of colonic epithelial barrier and bacterial translocation in rats. Am J Pathol 2005; 167: 1071-9.
32 Blanco-Melo D, Nilsson-Payant BE, Liu WC, et al. Imbalanced host response to SARS-CoV-2 drives development of COVID-19. Cell2020;181: 1036-45. e9.
33 Kempuraj D, Selvakumar GP, Ahmed ME, et al. COVID-19, mast cells, cytokine storm, psychological stress, and neuro-inflammation. Neuroscientist 2020; 26: 402-4.
34 Mabrey FL, Morrell ED, Wurfel MM. TLRs in COVID-19: how they drive immunopathology and the rationale for modulation. Innate Immun 2021; 27: 503-13.
35 Galván-Román JM, Rodríguez-García SC, Roy-Vallejo E, et al. IL-6 serum levels predict severity and response to tocilizumab in COVID-19: an observational study. J Allergy Clin Immunol 2021;147: 72-80. e8.
36 Higgins PG, Phillpotts RJ, Scott GM, Wallace J, Bernhardt LL, Tyrrell DA. Intranasal interferon as protection against experimental respiratory coronavirus infection in volunteers. Antimicrob Agents Chemother 1983; 24: 713-5.
37 Loutfy MR, Blatt LM, Siminovitch KA, et al. Interferon alfacon-1 plus corticosteroids in severe acute respiratory syndrome: a preliminary study. JAMA 2003; 290: 3222-8.
38 Sallard E, Lescure FX, Yazdanpanah Y, Mentre F, Peiffer-Smadja N, Type 1 interferons as a potential treatment against COVID-19. Antiviral Res 2020; 178: 104791.
39 Mantlo E, Bukreyeva N, Maruyama J, Paessler S, Huang C. Antiviral activities of type I interferons to SARS-CoV-2 infection. Antiviral Res 2020; 179: 104811.
40 Wang K, Yan HY, Wu S, Wang HQ, Li YH, Jiang JD. Inhibitory effect of Qing-Fei-Pai-Du decoction on coronavirus in vitro. Acta Pharmaceutica Sinica 2021; 56: 1400-8.
41 Zhang SY, He GL, Lu FG, et al. Mechanism research of antiinfluenza virus of ephedra decocted earlier Maxing Shigan decoction from the expression level of IFN-α/β protein mediated by TLR7/8. Zhong Hua Zhong Yi Yao Za Zhi 2019; 34: 1188-93.
42 Hadjadj J, Yatim N, Barnabei L, et al. Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients. Science 2020; 369: 718-24.
43 Schreiber G. The role of type I interferons in the pathogenesis and treatment of COVID-19. Front Immunol 2020; 11: 595739.
44 Hasselbalch HC, Skov V, Kj?r L, et al. COVID-19 as a mediator of interferon deficiency and hyperinflammation: rationale for the use of JAK1/2 inhibitors in combination with interferon. Cytokine Growth Factor Rev 2021; 60: 28-45.
Options
Outlines

/

〈 〉